Alpha Tau Medical (NASDAQ:DRTS) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a research note issued to investors on Friday,Benzinga reports. They currently have a $9.00 price objective on the stock.

Separately, Piper Sandler reaffirmed an “overweight” rating and set a $7.00 target price on shares of Alpha Tau Medical in a research report on Thursday, August 15th.

Alpha Tau Medical Trading Up 0.9 %

Shares of DRTS stock opened at $2.32 on Friday. Alpha Tau Medical has a 1 year low of $1.75 and a 1 year high of $3.40. The firm’s fifty day simple moving average is $2.28 and its 200 day simple moving average is $2.30. The firm has a market capitalization of $161.64 million, a P/E ratio of -5.40 and a beta of 0.77. The company has a current ratio of 10.99, a quick ratio of 11.60 and a debt-to-equity ratio of 0.08.

Institutional Investors Weigh In On Alpha Tau Medical

Institutional investors and hedge funds have recently made changes to their positions in the company. Aptus Capital Advisors LLC boosted its stake in shares of Alpha Tau Medical by 83.7% in the 2nd quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock valued at $56,000 after purchasing an additional 10,000 shares in the last quarter. Financial Guidance Group Inc. lifted its position in Alpha Tau Medical by 83.7% during the 2nd quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock worth $56,000 after buying an additional 10,000 shares in the last quarter. Caprock Group LLC acquired a new position in Alpha Tau Medical during the 2nd quarter worth about $59,000. Finally, Levin Capital Strategies L.P. lifted its position in Alpha Tau Medical by 2.6% during the 1st quarter. Levin Capital Strategies L.P. now owns 338,764 shares of the company’s stock worth $999,000 after buying an additional 8,641 shares in the last quarter. Institutional investors and hedge funds own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.